Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Non-Current Debt: 2021-2023

Historic Non-Current Debt for Candel Therapeutics (CADL) over the last 2 years, with Sep 2023 value amounting to $14.3 million.

  • Candel Therapeutics' Non-Current Debt fell 28.74% to $14.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was $14.3 million, marking a year-over-year decrease of 28.74%. This contributed to the annual value of $20.2 million for FY2022, which is 3507.50% up from last year.
  • According to the latest figures from Q3 2023, Candel Therapeutics' Non-Current Debt is $14.3 million, which was down 14.15% from $16.7 million recorded in Q2 2023.
  • Over the past 5 years, Candel Therapeutics' Non-Current Debt peaked at $20.2 million during Q4 2022, and registered a low of $560,000 during Q4 2021.
  • Its 3-year average for Non-Current Debt is $16.4 million, with a median of $19.5 million in 2022.
  • Per our database at Business Quant, Candel Therapeutics' Non-Current Debt surged by 3,507.50% in 2022 and then declined by 28.74% in 2023.
  • Over the past 3 years, Candel Therapeutics' Non-Current Debt (Quarterly) stood at $560,000 in 2021, then spiked by 3,507.50% to $20.2 million in 2022, then declined by 28.74% to $14.3 million in 2023.
  • Its Non-Current Debt was $14.3 million in Q3 2023, compared to $16.7 million in Q2 2023 and $19.0 million in Q1 2023.